BBN Cardio Therapeutics

bbn cardio therapeutics is a preclinical pharmaceutical company that uses a novel, chemocentric mechanism of action to treat cardiovascular and metabolic diseases our lead asset, pa/hda-212-31 targets excessive fat accumulation in the liver, which can lead to nonalcoholic fatty liver disease (nafld) and progress further to nonalcoholic steatohepatitis (nash). a provisional patent was filed with claims that include our composition and method for treating nafld and nash. no medicines have been approved to treat nafld or nash. pa/hda-216 targets atherosclerotic plaques, a major factor in heart attacks and stroke, the leading causes of death globally. in november 2017 bbn cardio therapeutics was awarded us patent 9,808,437 for a composition and method of treating atherosclerosis, the major factor in coronary heart disease, which is the leading cause of death in the us and worldwide. patents have also been filed in 6 other countries and the eu. bbn cardio therapeutics is a dba of burke & bo